Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bruges – page 13

209 clinical trials in Bruges, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bruges at a glance
209
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

209 trials in Bruges

Open in trial search

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:ADC Therapeutics SA

Progressive supranuclear palsy

Not recruiting

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Phenylbutyrate
  • Sponsor:Amylyx Pharmaceuticals Inc.

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+2

Not recruiting

Study on Subcutaneous Infliximab for Patients with Ulcerative Colitis, Crohn's Disease, or Unclassified Inflammatory Bowel Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Belgian IBD Research and Development

Prostate cancer

Not recruiting

Study of Stereotactic Body Radiotherapy with or without Darolutamide for Patients with Oligorecurrent Prostate Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Universitair Ziekenhuis Gent

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Celgene Corp.

Other cities in France

The busiest research cities in the country

All 379 cities in France

Clinical research in Bruges

What the registry says about research in the country

01 Pain Management Research

Studies focusing on innovative approaches to manage post-operative pain in patients undergoing shoulder arthroscopy, evaluating the effectiveness of various pain management protocols and their impact on morphine consumption.

  • Arthroscopic Surgery Pain Control
  • Post-operative Pain Management
  • Analgesic Requirements Assessment

Research aims to optimize pain control strategies following minimally invasive shoulder procedures.

02 Neurology & Headache Treatment

Innovative research exploring the therapeutic potential of ketamine and magnesium sulfate combination for treating resistant chronic cluster headaches, offering hope for patients who don't respond to conventional treatments.

  • Chronic Cluster Headache Management
  • Drug Repurposing Studies
  • Treatment-Resistant Pain Conditions

This research represents a novel approach to addressing severe neurological pain conditions through medication repurposing.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.